Immunome (IMNM) said late Wednesday it priced an underwritten public offering of about 19.4 million shares at $7.75 per share for expected gross proceeds of $150 million.
Immunome said it has granted the underwriters a 30-day option to purchase up to an additional 2.9 million shares.
The offering is expected to close on Friday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。